Product Description
For Osteoarthritis of the Knee
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Asahi Kasei Pharma
Company Location: TOKYO M0 1018101
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Osteoarthritis, Knee
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01122485 |
PG201-PT-001 | P2 |
Completed |
Osteoarthritis, Knee |
2009-09-01 |
2025-03-27 |
Patient Enrollment|Primary Endpoints |
|
NCT01576419 |
PG201-P3 | P3 |
Completed |
Osteoarthritis, Knee |
2011-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|